Veterinary Education Study Demonstrates Benefit of Self-Driven POCUS Learning Program with Butterfly iQ Vet
Study finds 94% of participants believe POCUS with Butterfly iQ Vet is useful in their education and 95% would like it in clinical rotations.
Butterfly logo
Butterfly iQ Vet

Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body, multi-species diagnostic imaging, today announced its position in a recent Journal of Veterinary Medical Education publication, which demonstrates feasibility and benefits of implementing a self-driven point-of-care ultrasound (POCUS) curriculum in a large animal teaching hospital, utilizing Butterfly iQ Vet.

The study was led by Cristobal Navas de Solis, LV, MS, PhD, Assistant Professor of Cardiology/Ultrasound and Internal Medicine at the University of Pennsylvania School of Veterinary Medicine (Penn Vet), and enrolled 94 student volunteers in a randomized controlled trial during their large animal clinical rotations.

After receiving a brief video introduction on Butterfly device operation and digital materials on common clinical scenarios for POCUS in large animal teaching hospitals and equine health, participants were randomly assigned to access the Butterfly iQ device or not. For those granted access, self-driven use of POCUS was permitted to aid their examinations. There were no preplanned lectures, exercises, or practice requirements – but students could request help from faculty to support self-motivated scanning, as needed.

“By equipping students with POCUS devices, we demonstrated the feasibility of implementing self-driven POCUS training in a large animal teaching hospital, even amid the heavy caseloads and time-constraints faced in such an environment. Moreover, we found that this self-driven program increased POCUS knowledge in students that have lower test scores.” Dr. Cristobal Navas de Solis shared.

Notably, the research found that 94% of participating students perceived POCUS to be useful in their education and 95% would like a POCUS probe during all their clinical rotations. The most valuable program aspects reported were: access to the equipment, the hands-on learning approach, the ability to scan independently, and having clinician help when needed.

Dr. Solis concluded, “As an educator who continually seeks to focus, engage, and motivate students, it’s outstanding to see this attitude toward self-motivated learning.”

“Supporting academic institutions in educating and training the next generation of POCUS-proficient, confident veterinary professionals is core to what we do at Butterfly,” said David Rousseau, DVM, Butterfly Network’s Veterinary Clinical Director. “This research corroborates our belief that by empowering students with Butterfly’s easy-to-operate, pocket-sized POCUS system, we can greatly enhance training efficiencies and knowledge outcomes.”

Veterinarians can learn more information about Butterfly iQ+ Vet at: vet.butterflynetwork.com.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011 and listed on the NYSE through a merger with Longview Acquisition Corp (NYSE: BFLY), Butterfly Network is the creator of the world’s most advanced handheld, single-probe, whole-body veterinary ultrasound system, Butterfly iQ+ Vet.

Butterfly’s mission is to enable universal access to superior medical imaging, and part of that mission is to enable the scanning of every animal at each veterinary visit. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ Vet can be purchased online by veterinary practitioners in approved countries at the store or by contacting sales.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development of products and services, and the size and potential growth of current or future markets for its products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business, including issues relating to Omicron or other variants; the ability to recognize the anticipated benefits of the business combination; the Company’s ability to grow and manage growth profitably; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; manufacturing and supply of the Company’s products; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using its products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in the Company’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. The Company does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

Newsletter

Don’t miss the latest in equine health/research and vet business/vet health/industry news from EquiManagement’s Newsletters!

"*" indicates required fields

Name*
Country*
This field is for validation purposes and should be left unchanged.